To evaluate the risk of PC both at the time of diagnosis and following treatment, various factors are taken into consideration, including the grading system, PSA level, tumor–node–metastasis classification (TNM), and the patient’s treatment history. The gene discussed is KLK3; the disease is neoplasm.